Business Wire

CA-VISA

Share
Visa Joins AWS Partner Network to Help Simplify Global Digital Payments

Visa (NYSE: V), a world leader in global digital payments, announced today it has joined the AWS Partner Network (APN), a global community that leverages AWS technologies, programs, expertise, and tools to build solutions and services for customers. Visa’s presence in the APN will help enable its partners and clients, including cloud-native fintechs, to access and integrate select Visa services more efficiently.

Global Payments Simplified

Visa is committed to making transactions faster, easier and more secure for all players in the payments ecosystem. Visa will make select payment services available in the AWS Marketplace, which has more than 300,000 global customers and thousands of software listings.

By making its services available in AWS, Visa is meeting its clients where they are. One of the first services to be available is Visa Cross-Border Solutions, which assists in streamlining the process of sending and receiving money globally and holding multiple currencies. This strategic positioning will allow Visa’s clients to integrate solutions like Visa Cross-Border Solutions into their business operations - eliminating the need for them to step out of their established platforms.

“Visa is dedicated to better serving our clients in cloud environments, which is why we’re excited to bring Visa Cross-Border Solutions to the AWS Marketplace,” said Vanessa Colella, Global Head of Innovation and Digital Partnerships, Visa. “We aim to make our solutions readily accessible and available for customers to easily integrate across diverse platforms. This is a step further in our broader commitment to reduce challenges for financial institutions and enterprises.”

Cloud-Based Connectivity

Through AWS, Visa plans to bring more of its products to clients operating in the cloud. Companies wanting to process payments through AWS on VisaNet, Visa’s global processing network, can already establish secure AWS Privatelink connectivity with Visa Cloud Connect.

Cloud-native fintechs, financial institutions, and enterprises have found using cloud services can help accelerate service deployment and customer adoption. It can also contribute to lowering costs associated with local data centers, implementing specialized hardware like physical routers, and payment hardware security modules (HSMs).

“As a cloud-native card issuer and processor, and one of the first issuer processors in Europe to connect to the Visa Cloud Connect endpoint in the EU, we believe the enablement of Visa services through AWS is a gamechanger,” said Merusha Naidu, Global Head of Partnerships, Paymentology. “This partnership paves the way for enhanced digital payment solutions, providing startups with the tools they need to innovate and thrive in today's fast-paced landscape.”

Empowering Startups with Fintech Solutions

Visa is also proud to announce that it is now part of AWS Activate, AWS’s flagship startup program. Fintech clients enrolled in the Visa Fintech Fast Track program, and verified by AWS as eligible, can receive up to $100,000 in AWS Activate credits to help jumpstart their growth and reduce their time to market.

"We are excited to support the expansion of digital payments, banking, and embedded finance capabilities to enterprises and fintech startups building their applications on AWS,” said Howard Wright, VP and Global Head of Startups at AWS. “We are looking forward to working with Visa to help make financial apps in the cloud more accessible, faster, secure, and easier to use.”

Many startups running on AWS have already benefited from Visa programs like Visa Ready and Fintech Fast Track.

About Visa

Visa (NYSE: V) is a world leader in digital payments, facilitating transactions between consumers, merchants, financial institutions, and government entities across more than 200 countries and territories. Our mission is to connect the world through the most innovative, convenient, reliable, and secure payments network, enabling individuals, businesses and economies to thrive. We believe that economies that include everyone everywhere, uplift everyone everywhere and see access as foundational to the future of money movement. Learn more at Visa.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240425648724/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye